These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10866433)

  • 1. Youth and hormone receptors in breast cancer: good or bad news first?
    Stockler M; Beith J
    Lancet; 2000 May; 355(9218):1839-40. PubMed ID: 10866433
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
    Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
    Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
    Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
    J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian suppression for breast cancer: an effective treatment in search of a home.
    Krop IE; Winer EP
    J Clin Oncol; 2005 Sep; 23(25):5869-72. PubMed ID: 16087947
    [No Abstract]   [Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
    Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
    Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
    Rydén L; Jönsson PE; Chebil G; Dufmats M; Fernö M; Jirström K; Källström AC; Landberg G; Stål O; Thorstenson S; Nordenskjöld B; ;
    Eur J Cancer; 2005 Jan; 41(2):256-64. PubMed ID: 15661551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
    Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
    Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF.
    Sanchez BC; Sundqvist M; Fohlin H; Spyratos F; Nordenskjöld B; Stål O; Linderholm BK
    Eur J Cancer; 2010 Jun; 46(9):1580-7. PubMed ID: 20413297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen replacement therapy for the breast cancer survivor.
    DiSaia PJ
    J Soc Gynecol Investig; 1996; 3(2):57-9. PubMed ID: 8796808
    [No Abstract]   [Full Text] [Related]  

  • 15. HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
    Ferretti G; Di Cosimo S; Giannarelli D; Carlini P; Papaldo P; Alimonti A; Fabi A; Mandalà M; Milella M; Ruggeri EM; Cognetti F
    J Clin Oncol; 2004 Feb; 22(3):568-9. PubMed ID: 14752083
    [No Abstract]   [Full Text] [Related]  

  • 16. [Tamoxifen-induced progesterone receptors in breast tumors].
    Tsyrlina EV; Semiglazov VF; Nurgaziev KSh; Ivanova OA
    Vopr Onkol; 1991; 37(9-10):916-21. PubMed ID: 1842650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen in early breast cancer.
    Arriagada R
    Lancet; 1998 Aug; 352(9125):403-4. PubMed ID: 9717953
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Dellapasqua S; Colleoni M; Gelber RD; Goldhirsch A
    J Clin Oncol; 2005 Mar; 23(8):1736-50. PubMed ID: 15755982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.